Guangdong Zhongsheng Pharmaceutical (002317.SZ): The first participant has been enrolled in the Phase II clinical trial of Angladivir granules.

Guangdong Zhongsheng Pharmaceutical (002317.SZ) announced that its subsidiary, Guangdong Zhongsheng Ruichuang Biotechnology Co., Ltd. (referred to as "Zhongsheng Ruichuang"), has successfully completed the first participant enrollment and dosing in the Phase II clinical trial of a class of innovative drug called Angladawir granules (research code: ZSP1273 granules) for the treatment of patients aged 2 to 17 with uncomplicated influenza A.